Safety and Effectiveness of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist Diphenhydraminein Advanced and Metastatic Non-Small Cell Lung Cancer: A Prospective, Randomized-controlled, Multi-center, Open-label, Phase-III Trial

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tislelizumab (Primary) ; Carboplatin; Cisplatin; Diphenhydramine; Paclitaxel; Pemetrexed
Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

11 Dec 2024 Planned End Date changed from 1 Oct 2027 to 1 Nov 2027.
11 Dec 2024 Planned primary completion date changed from 1 Oct 2026 to 1 Nov 2026.
11 Dec 2024 Planned initiation date changed from 1 Nov 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight